[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100375064":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":53,"collaborators":12,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":12,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":12,"enrollmentInfo":64,"targetDuration":12,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":38,"whyStopped":12,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"VA Office of Research and Development","FED",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","Participants in the control group will have their blood pressure, fluid status, as well as all other aspects of clinical care managed in entirety by their treating nephrologists.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"IBPS (Intradialytic Blood Pressure Slope) Arm","EXPERIMENTAL","IBPS participants will have their target weight adjusted each month by the study investigator based on recent assessment of intradialytic blood pressure slopes.",[18],"Other: IBPS-Guided Ultrafiltration",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"OTHER","IBPS-Guided Ultrafiltration","Each month, the study investigator will review the average intradialytic blood pressure slope from the prior two weeks. A prespecified algorithm will be used to prescribe additional fluid removal\u002Fweight reduction based on this slope.",[14],[26],{"name":27,"affiliation":28,"role":29},"Peter Noel Van Buren, MD","VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":12,"email":35},"Peter N Van Buren, MD","CONTACT","(214) 857-2214","peter.vanburen@va.gov",[37],{"facility":28,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Dallas","Texas","75216-7167","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-96.80667,32.78306,{"lat":48,"lon":47},[51,52],{"name":32,"role":33,"phone":34,"phoneExt":12,"email":35},{"name":27,"role":29,"phone":12,"phoneExt":12,"email":12},{"type":54,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100375064","blood-pressure-slopes-and-ultrafiltration-in-hemodialysis-patients-100375064",false,"NCT04163614","Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients","Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration in Hemodialysis Patients","Inclusion Criteria:\n\n* Hemodialysis patient\n* Pre-dialysis systolic blood pressure greater than 140 mmHg averaged over 2 weeks OR post-dialysis systolic blood pressure greater than 130 mmHg averaged over 2 weeks\n\nExclusion Criteria:\n\n* HemoDialysis Vintage Less than 2 months\n* Pregnancy\n* Mean systolic blood pressure nadir \\\u003C95 mmHg in 2 weeks screening\n* Mean pre- or post-dialysis systolic blood pressure \\>180 mmHg\n* Mean pre to post-HD decrease in blood pressure \\>60 mmHg\n* Routine intradialytic clonidine use\n* Routine intradialytic midodrine use\n* Documented antihypertensive medication non-adherence\n* Mean ultrafiltration rate \\>13 mL\u002Fkg\u002Fhr during 2 week screening\n* For bioimpedance measurements only: amputation of a major extremity, presence of cardiac defibrillator or pacemaker, presence of a metallic implant (prosthetic joint)","ALL","18 Years",{"count":65,"type":66},69,"ESTIMATED","INTERVENTIONAL",[69],"NA","Kidney failure has been recognized as one of the most costly chronic conditions among United States Veterans. Approximately 13,000 Veterans develop kidney failure each year, and most require hemodialysis initiation. Hemodialysis patients suffer significantly increased risk of death and hospitalizations, and excessive body fluid is a major cause of this. While empiric aggressive fluid removal during dialysis is one approach to limit fluid overload, this can cause dangerous decreases in blood pressure during dialysis that independently contribute to the high death rate. In this study, I aim to test a new strategy that prescribes fluid removal based on a patient's recent blood pressure patterns during dialysis. This clinical trial will compare my strategy to standard care and assess the outcomes of overall blood pressure change between dialysis treatments in addition to the number of times the blood pressure becomes dangerously low during dialysis. Another aim is to determine how differences in the structure and function of the heart influence blood pressure during dialysis.",[72,73,74,75],"End Stage Renal Disease","Hypertension","Extracellular Volume Overload","Intradialytic Hypotension",[72,73,77,75,78],"Extracellular Volume","Bioimpedance Spectroscopy","2026-01-05",{"date":81,"type":82},"2026-01-07","ACTUAL",{"date":84,"type":82},"2021-02-10",{"date":86,"type":66},"2026-07-01",{"name":5,"class":6},1]